Targeting CXADR Suppresses Tumorigenesis And Enhances Chemotherapy Efficacy In Ewing Sarcoma

Researchers recently discovered that a specific viral receptor gene called CXADR is highly active in patients with the worst Ewing Sarcoma survival rates. When CXADR is active, it triggers a chain reaction in cells called the AKT signaling pathway, which allows tumor cells to change shape, break away, and aggressively spread throughout the body. By successfully blocking this gene in laboratory experiments, scientists were able to significantly shrink local tumors, induce cancer cell death, and drastically halt the spread of the disease to distant organs.

To turn this discovery into a practical medical treatment, the researchers tested a breast cancer drug called Capivasertib, which is already designed to block that exact AKT signaling pathway. They discovered that tumors with the highest levels of CXADR were the most sensitive to this drug, and combining it with standard chemotherapy made it up to three times more effective. Ultimately, this research provides a promising blueprint for personalized medicine. Doctors could potentially test an Ewing Sarcoma patient’s specific CXADR levels to safely predict if this targeted drug combination will help them beat the cancer.

Read the full article